Australia's Arovella Therapeutics jumps on positive US FDA feedback

Arovella Therapeutics

07/08/2024 03:08

** Shares of biotechnology co Arovella Therapeutics  ALA.AX 
rise as much as 10.3% to A$0.160
    ** Co says it received positive feedback from the U.S. Food
and Drug Administration during a pre-investigational meeting for
ALA-101
        ** Feedback supported development plans to commence a
phase 1, first-in-human clinical trial, co says
  
    ** ALA-101 is a treatment for CD19+ type blood cancers
    ** ALA up 26.1% YTD, as of last close

 (Reporting by Adwitiya Srivastava in Bengaluru)
 ((Adwitiya.Srivastava@thomsonreuters.com;))